用系统化数据分类量化临床试验中收集的数据类型:DataCat项目
该研究制定标准操作流程,将18项随机优效性试验的数据采集表变量分为主要结局、次要结局及15类其他数据并计算占比。结果显示主要结局数据仅占5.0%(中位数)/11.2%(均值),次要结局占39.9%(中位数)/42.5%(均值),非结局数据占32.4%(中位数)/36.5%(均值)。作者建议试验者只收集对支持健康和治疗决策必需的数据。
要点
- 主要结局数据仅占全部数据项的5.0%(中位数)/11.2%(均值)。
- 次要结局数据量约为主要结局的八倍,占39.9%(中位数)/42.5%(均值)。
- 非结局数据(如参与者标识和人口学数据)占32.4%(中位数)/36.5%(均值)。
核心结论
- 在18项试验样本中,与主要结局相关的数据仅占小部分,次要结局数据量约为主要结局的八倍,大量数据收集与试验结局无关。
研究设计与样本
- 制定标准操作流程,将数据分为主要结局、次要结局和15类其他类别。
- 对18项主要为公共资助的随机优效性试验的数据采集表变量进行分类,包括研究性药品试验和复杂干预试验。
- 分类由两人独立完成,一人深入了解试验,另一人独立于试验,分歧参照试验方案讨论解决。
主要发现
- 主要结局数据占全部数据项的5.0%(中位数)/11.2%(均值)。
- 次要结局数据占全部数据项的39.9%(中位数)/42.5%(均值)。
- 非结局数据(如参与者标识和人口学数据)占全部数据项的32.4%(中位数)/36.5%(均值)。
临床怎么用
- 试验者应确保只收集对支持试验目标人群健康和治疗决策必需的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data collection consumes a large proportion of clinical trial resources. Each data item requires time and effort for collection, processing and quality control procedures. In general, more data equals a heavier burden for trial staff and participants. It is also likely to increase costs. Knowing the types of data being collected, and in what proportion, will be helpful to ensure that limited trial resources and participant goodwill are used wisely. AIM: The aim of this study is to categorise the types of data collected across a broad range of trials and assess what proportion of collected data each category represents. METHODS: We developed a standard operating procedure to categorise data into primary outcome, secondary outcome and 15 other categories. We categorised all variables collected on trial data collection forms from 18, mainly publicly funded, randomised superiority trials, including trials of an investigational medicinal product and complex interventions. Categorisation was done independently in pairs: one person having in-depth knowledge of the trial, the other independent of the trial. Disagreement was resolved through reference to the trial protocol and discussion, with the project team being consulted if necessary. KEY RESULTS: Primary outcome data accounted for 5.0% (median)/11.2% (mean) of all data items collected. Secondary outcomes accounted for 39.9% (median)/42.5% (mean) of all data items. Non-outcome data such as participant identifiers and demographic data represented 32.4% (median)/36.5% (mean) of all data items collected. CONCLUSION: A small proportion of the data collected in our sample of 18 trials was related to the primary outcome. Secondary outcomes accounted for eight times the volume of data as the primary outcome. A substantial amount of data collection is not related to trial outcomes. Trialists should work to make sure that the data they collect are only those essential to support the health and treatment decisions of those whom the trial is designed to inform.
引用
- Crowley E, Treweek S, Banister K, et al. Using systematic data categorisation to quantify the types of data collected in clinical trials: the DataCat project. Trials. 2020. PMID: 32546192. doi:10.1186/s13063-020-04388-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。